Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simvastatin for Alcohol-Related Advanced Liver Fibrosis
2024-519968-41-00Phase 3Authorised
- Sponsor
- IDIBAPS
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in alcoholic liver disease (ALD), chronic liver disease (CLD) and hepatic fibrosis comparing Simvastatina NORMON with Placebo (2 arms). Primary endpoint: Change in histological fibrosis score (Ishak scale) at 24 months. Planned start Dec 2024; status: authorised.
02
Drugs
Simvacard
03
Conditions
alcoholic liver disease (ALD)chronic liver disease (CLD)hepatic fibrosis
Beyond the preview
Go deeper on 2024-519968-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519968-41-00.